GSK plc (NYSE:GSK) Position Lessened by Choreo LLC

Choreo LLC trimmed its position in shares of GSK plc (NYSE:GSK) by 3.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,751 shares of the pharmaceutical company’s stock after selling 1,929 shares during the period. Choreo LLC’s holdings in GSK were worth $1,776,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Eastern Bank purchased a new stake in shares of GSK during the third quarter worth $26,000. Sunbelt Securities Inc. increased its position in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the last quarter. Crews Bank & Trust acquired a new position in GSK during the fourth quarter worth $26,000. Concord Wealth Partners increased its position in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares during the last quarter. Finally, ST Germain D J Co. Inc. increased its position in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 522 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on GSK. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and lowered their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Six investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Trading Down 1.0 %

Shares of NYSE:GSK opened at $36.03 on Friday. The company has a market cap of $74.68 billion, a P/E ratio of 23.40, a P/E/G ratio of 1.38 and a beta of 0.64. The stock’s 50-day moving average is $34.21 and its 200-day moving average is $37.60. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 50.62% and a net margin of 7.97%. Equities research analysts predict that GSK plc will post 3.92 earnings per share for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a yield of 4.36%. GSK’s dividend payout ratio (DPR) is 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.